NO20045460L - Behandling av T-cellemedierte autoimmune forstyrrelser - Google Patents

Behandling av T-cellemedierte autoimmune forstyrrelser

Info

Publication number
NO20045460L
NO20045460L NO20045460A NO20045460A NO20045460L NO 20045460 L NO20045460 L NO 20045460L NO 20045460 A NO20045460 A NO 20045460A NO 20045460 A NO20045460 A NO 20045460A NO 20045460 L NO20045460 L NO 20045460L
Authority
NO
Norway
Prior art keywords
treatment
cell mediated
mediated autoimmune
autoimmune disorders
oophoritis
Prior art date
Application number
NO20045460A
Other languages
English (en)
Inventor
Randolph J Noelle
Eric Claassen
Original Assignee
Tno
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Publication of NO20045460L publication Critical patent/NO20045460L/no
Application filed by Tno filed Critical Tno

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Det er beskrevet anvendelse av en gp39-antagonist ved fremstilling av et medikament egnet til behandling av en T-cellemediert autoimmunsykdom valgt blant EAE (eksperimentell allergisk encefalomyelitt), diabetes type I, oophoritis og tyroiditis.
NO20045460A 1995-06-07 2004-12-15 Behandling av T-cellemedierte autoimmune forstyrrelser NO20045460L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/481,735 US5833987A (en) 1995-06-07 1995-06-07 Treatment of T cell mediated autoimmune disorders
PCT/US1996/009137 WO1996040246A1 (en) 1995-06-07 1996-06-06 Treatment of t cell mediated autoimmune disorders

Publications (1)

Publication Number Publication Date
NO20045460L true NO20045460L (no) 1998-02-06

Family

ID=23913182

Family Applications (2)

Application Number Title Priority Date Filing Date
NO19975520A NO322391B1 (no) 1995-06-07 1997-12-01 Anvendelse av en gp39-antagonist ved fremstilling av et medikament egnet til behandling av ikke-B-lymfocytt-mediert vevsdestruksjon assosiert med multippel sklerose.
NO20045460A NO20045460L (no) 1995-06-07 2004-12-15 Behandling av T-cellemedierte autoimmune forstyrrelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO19975520A NO322391B1 (no) 1995-06-07 1997-12-01 Anvendelse av en gp39-antagonist ved fremstilling av et medikament egnet til behandling av ikke-B-lymfocytt-mediert vevsdestruksjon assosiert med multippel sklerose.

Country Status (17)

Country Link
US (4) US5833987A (no)
EP (2) EP1161954A1 (no)
JP (1) JPH11507058A (no)
KR (1) KR100493482B1 (no)
CN (2) CN1192156A (no)
AT (1) ATE214944T1 (no)
AU (1) AU705623B2 (no)
CA (1) CA2223303A1 (no)
DE (1) DE69620174T2 (no)
DK (1) DK0831906T3 (no)
ES (1) ES2177791T3 (no)
HU (1) HUP9900857A3 (no)
NO (2) NO322391B1 (no)
NZ (1) NZ311276A (no)
PT (1) PT831906E (no)
WO (1) WO1996040246A1 (no)
ZA (1) ZA964851B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
NZ337073A (en) * 1997-01-10 2001-01-26 Biogen Inc use of an anti CD40L compound to treat a patient with an autoimmune disease or chronic immune system disorder
WO1999000143A1 (en) * 1997-06-27 1999-01-07 Biogen, Inc. Cd154 blockade therapy for autoimmune diseases
CN1173735C (zh) * 1998-04-03 2004-11-03 达特茅斯学院理事 抗-gp39抗体在狼疮及相关肾病的治疗和/或逆转中的应用
US20030077667A1 (en) * 1999-06-01 2003-04-24 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US20070160615A1 (en) * 1999-06-01 2007-07-12 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of Alzheimer's disease
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
AU5914201A (en) * 2000-04-25 2001-11-07 Idec Pharma Corp Intrathecal administration of rituximab for treatment of central nervous system lymphomas
BR0110779A (pt) 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
WO2001094586A2 (en) * 2000-06-06 2001-12-13 Idec Pharmaceuticals Corporation Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
US20040146949A1 (en) * 2002-10-25 2004-07-29 Jun Tan Methods and compounds for disruption of CD40R/CD40L signaling in the treatment of alzheimer's disease
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
GB0707208D0 (en) * 2007-04-13 2007-05-23 Istituto Superiore Di Sanito Novel disease treatments
PE20091420A1 (es) * 2007-11-13 2009-10-17 Evec Inc ANTICUERPOS MONOCLONALES ANTI hGM-CSF
EP2229914B1 (en) * 2009-03-20 2018-05-30 Nobel Biocare Services AG System and method for aligning virtual models
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
KR101614739B1 (ko) * 2015-12-01 2016-04-22 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
CN110662768B (zh) 2017-05-24 2024-01-30 Als治疗发展学会 治疗性抗cd40配体抗体
WO2019175332A1 (en) 2018-03-14 2019-09-19 Imba - Institut Für Molekulare Biotechnologie Gmbh Bh4 pathway inhibition and use thereof for treating t-cell mediated autoimmune diseases or hypersensitivity

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5192773A (en) * 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) * 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
US5571507A (en) * 1992-02-25 1996-11-05 Seragen, Inc. Methods of treating diabetes
US5958403A (en) * 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
WO1994028912A1 (en) * 1993-06-10 1994-12-22 The Regents Of The University Of Michigan Cd28 pathway immunosuppression
DK0721469T3 (da) * 1993-09-02 2000-05-01 Dartmouth College Anti-gp39-antistoffer og anvendelse deraf
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders

Also Published As

Publication number Publication date
EP0831906A1 (en) 1998-04-01
US20020009450A1 (en) 2002-01-24
KR100493482B1 (ko) 2005-08-29
US5833987A (en) 1998-11-10
EP1161954A1 (en) 2001-12-12
JPH11507058A (ja) 1999-06-22
WO1996040246A1 (en) 1996-12-19
ZA964851B (en) 1997-07-29
CN1192156A (zh) 1998-09-02
ES2177791T3 (es) 2002-12-16
US20040197327A1 (en) 2004-10-07
EP0831906B1 (en) 2002-03-27
AU6255996A (en) 1996-12-30
DE69620174T2 (de) 2002-07-18
NO322391B1 (no) 2006-10-02
KR19990022273A (ko) 1999-03-25
HUP9900857A3 (en) 1999-11-29
DE69620174D1 (de) 2002-05-02
US6328964B1 (en) 2001-12-11
CA2223303A1 (en) 1996-12-19
NZ311276A (en) 1999-11-29
NO975520D0 (no) 1997-12-01
DK0831906T3 (da) 2002-05-21
NO975520L (no) 1998-02-06
ATE214944T1 (de) 2002-04-15
HUP9900857A2 (hu) 1999-07-28
AU705623B2 (en) 1999-05-27
PT831906E (pt) 2002-09-30
CN1827168A (zh) 2006-09-06

Similar Documents

Publication Publication Date Title
NO20045460L (no) Behandling av T-cellemedierte autoimmune forstyrrelser
US6066092A (en) Preemptive prophylaxis of migraine device and method
DE122009000064I1 (de) Pharmazeutische Zubereitung enthaltend Pioglitazone und Glimepiride zur Verwendung in der Behandlungvon Diabetes.
CA2275504A1 (en) Pharmacogenetic methods for use in the treatment of nervous system diseases
MA26658A1 (fr) Derivés de valérohydrazine, procédé pour les préparer, médicament pour le traitement des maladies inflammatoires et auto-immunes les contenant, et leur utilisation pour préparer un tel médicament
Vignau Preliminary assessment of a 10-day rapid detoxification programme using high dosage buprenorphine
AU6314296A (en) Therapeutic agents and autoimmune diseases
EP2357223A3 (en) Human stem cell material and methods
DE69819922D1 (de) 2-Amino-6-methyl-7-acetyl-tetralin und pharmazeutische Zusammensetzungen zur Vorbeugung und therapeutischen Behandlung von entzündlichen und/oder Autoimmunkrankheiten
DK0883406T3 (da) Anvendelse af IL-7 til behandling af autoimmune sygdomme og især insulinafhængig diabe-tesmellitus i særdeleshed
RU97111763A (ru) Способ подбора антибактериальных препаратов для лечения гнойно-воспалительных процессов
De Graaf et al. The Weber-curve pitfall: effects of a forced introduction on reporting rates and reported adverse reaction profiles
Hladik et al. Evaluation of written reinforcements used in counseling cardiovascular patients
Lessenger Acculturation and MMPI-2 scale scores of Mexican American substance abuse patients
EA200301128A1 (ru) Однократная доза ингибитора ароматазы для лечения бесплодия
Ginzburg et al. The role of naltrexone in the management of drug abuse
AU3065789A (en) Clinical testing, monitoring and pharmaceutical compositions for treatment of auto-immune diseases
EP0974361A4 (en) METHOD FOR USE OF AN ACID BINDING AGENT AND A PHARMACEUTICAL PREPARATION CONTAINING AN ACID BINDING AGENT
EP0408525A3 (en) Use in therapy of 10-amino-5,6-dihydro-11h-dibenzo(b,e)azepine-6,11-dione and derivatives as drugs for use in the treatment of urinary incontinence
Gelfand et al. Speech recognition performance on a modified nonsense syllable test
RU96114864A (ru) Способ прогнозирования эффективности нейротропных средств при аллергии
James D4T: new clinical data confirms benefit
Jablow Depression and MS.
UA39711A (uk) Спосіб лікування розсіяного склерозу
Koch-Weser PREDICTION OF THE THERAPEUTIC EFFECTIVENESS OF NEW DRUGS FROM CLINICAL PHARMACOLOGY STUDIES

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application